# BUY Zomato

# Blinkit continues to drive outperformance

# Information Technology > Result Update > May 14, 2024

Zomato posted steady operational results, with revenue ahead of our estimates whereas the margin miss was on account of higher than expected ESOP costs (for the Blinkit leadership team). Food delivery GOV grew 28.5% YoY to Rs84.4bn (-0.6% QoQ), with Blinkit GOV up 13.7% QoQ/96.8% YoY to Rs40.3bn. Blinkit achieved operational EBITDA break-even in Mar-2024. Management guided to Blinkit remaining closer to break-even levels at adjusted EBITDA for the next few quarters, considering the aggressive store expansion plan (~2x in 12M). Most of the store expansion should happen in the top-8 cities, where Management sees significant scope for growth as Company is still largely underpenetrated. We have mostly retained FY26E EPS, but lowered FY25E EPS by ~20%, factoring in the slower profitability for Blinkit on the aggressive store addition plan and higher ESOP costs. We maintain BUY and TP of Rs230/sh on SOTP basis, valuing food delivery at Rs121/sh (DCF basis), Blinkit at Rs93/sh (DCF basis), and cash & other investments at Rs17/sh (BV).

| Zomato: Financial Snapshot (Consolidated) |          |          |          |          |          |  |  |  |
|---|----------|----------|----------|----------|----------|--|--|--|
| Y/E Mar (Rs mn)                           | FY22     | FY23     | FY24     | FY25E    | FY26E    |  |  |  |
| Revenue                                   | 41,924   | 70,792   | 1,21,140 | 1,72,573 | 2,33,795 |  |  |  |
| EBITDA                                    | (18,508) | (12,105) | 420      | 11,924   | 29,299   |  |  |  |
| Adj. PAT                                  | (15,061) | (9,716)  | 3,510    | 15,414   | 31,378   |  |  |  |
| Adj. EPS (Rs)                             | (1.7)    | (1.1)    | 0.4      | 1.7      | 3.4      |  |  |  |
| EBITDA margin (%)                         | (44.1)   | (17.1)   | 0.3      | 6.9      | 12.5     |  |  |  |
| EBITDA growth (%)                         | NM       | NM       | NM       | 2,738.9  | 145.7    |  |  |  |
| Adj. EPS growth (%)                       | NM       | NM       | NM       | 339.1    | 116.0    |  |  |  |
| RoE (%)                                   | (12.2)   | (5.4)    | 1.8      | 7.3      | 13.3     |  |  |  |
| RoIC (%)                                  | (131.5)  | (41.1)   | (9.7)    | 10.5     | 39.0     |  |  |  |
| P/E (x)                                   | (117.4)  | (182.6)  | 505.5    | 115.1    | 56.5     |  |  |  |
| EV/EBITDA (x)                             | (89.2)   | (137.3)  | 3,933.9  | 137.2    | 54.6     |  |  |  |
| P/B (x)                                   | 10.7     | 9.1      | 8.7      | 8.1      | 7.1      |  |  |  |
| FCFF yield (%)                            | (0.5)    | (0.6)    | 0.3      | 0.9      | 2.1      |  |  |  |
| Sources Company Emkou                     | Decearch |          |          |          |          |  |  |  |

Source: Company, Emkay Research

# **Results Summary**

Zomato reported revenue growth of 8.3% QoQ to Rs35.6bn, slightly ahead of our estimate of Rs34.8bn. All segments reported sequential growth, with food delivery/ Hyperpure/ Quick Commerce/Going Out growing 2%/11%/19%/27%. Food delivery GOV declined 0.6% QoQ/grew 28.5% YoY. Average MTU grew 1.1% QoQ to 19mn. Blinkit GOV grew 13.7% QoQ to Rs40.3bn, and saw breakeven on adj. EBITDA basis for the first time, in Mar-24. Overall adjusted revenue grew 6.2% QoQ to Rs38.7bn. Contribution margin for food delivery improved further to 7.5% from 7.1% in Q3. Blinkit's contribution margin improved to 3.9% in Q4 from 2.4% in Q3. Adjusted EBITDAM as a % of GOV improved to 3.3% (from 3% in Q3), whereas Blinkit's adjusted EBITDAM improved to -0.9% (from -2.5% in O3). Overall adjusted EBITDAM improved to 5% from 3.4% in O3. What we liked: Strong growth, coupled with adjusted breakeven for Mar-24 for Blinkit. What we did not like: Slower expansion in Blinkit margin, higher ESOP costs.

## Earnings Call KTAs

i) Total ESOP charge for Q4 was Rs1.61bn vs Rs1.22bn QoQ. Management expects ESOP charge to increase further in FY25 due to grant of ESOPs to the Blinkit leadership team and senior employees. ii) Company proposed to create an additional ESOP pool of 2% of outstanding share capital on a fully diluted basis which Management expects would suffice for the next 5-6 years. iii) Revenue growth in Q4 was driven by robust growth in both, food delivery and quick commerce. iv) Adj EBITDAM (food delivery) improved by 210bps YoY, driven by: a) higher AOV, b) improvement in take rate and ad monetization, c) introduction of platform fee, and d) cost efficiencies, which were more than compensated for the lower customer delivery fee on account of free delivery benefit on Gold orders. v) In FY24, Food delivery ATU grew 10% YoY. vi) Company added 75 net new dark stores for Blinkit in Q4 (80% of new stores are in the top-8 cities). Company expects adding another 100 stores in Q1FY25 and reaching a store-count of ~1,000 by Mar-25. vii) With the planned store addition in FY25, Management expects adj. EBITDA (QC) to hover at around zero for the next few quarters. In steady state, it expects 4-5% adj. EBITDAM (as a % of GOV). viii) Though Blinkit is present in 26 cities, it focuses on expanding in the top-8 cities in India. Other cities are catching-up, but Delhi NCR (the largest market) is growing at 7% QoQ, driven by addition of new stores and growth in demand from existing stores. Bengaluru is the second-largest market with less than 30% of Delhi NCR's GOV. Avg. GOV of the next 6 cities is ~Rs1.93bn, with 32 stores. It plans to grow its presence in Bengaluru and other large cities which will lead to ~4x increase in GOV. ix) Blinkit take rate increased 1% QoQ on the back of increase in commission, advertisement, assortment mix, and delivery charges.



# **TARGET PRICE (Rs): 230**

| Target Price – 12M    | Mar-25 |
|-----------------------|--------|
| Change in TP (%)      | -      |
| Current Reco.         | BUY    |
| Previous Reco.        | BUY    |
| Upside/(Downside) (%) | 18.4   |
| CMP (13-May-24) (Rs)  | 194.3  |
| Stock Data            | Ticker |
| 52-week High (Rs)     | 207    |
| 52-week Low (Rs)      | 62     |

| Shares outstanding (mn) | 8,827.0   |
|-------------------------|-----------|
| Market-cap (Rs bn)      | 1,715     |
| Market-cap (USD mn)     | 20,533    |
| Net-debt, FY25E (Rs mn) | 0         |
| ADTV-3M (mn shares)     | 55        |
| ADTV-3M (Rs mn)         | 9,413.0   |
| ADTV-3M (USD mn)        | 112.7     |
| Free float (%)          | 48.0      |
| Nifty-50                | 22,104    |
| INR/USD                 | 83.5      |
| Shareholding, Mar-24    |           |
| Promoters (%)           | -         |
| FPIs/MFs (%)            | 55.1/15.3 |

| Price Performance |     |      |       |  |  |  |
|-------------------|-----|------|-------|--|--|--|
| (%)               | 1M  | 3M   | 12M   |  |  |  |
| Absolute          | 1.1 | 25.6 | 210.4 |  |  |  |
| Rel. to Nifty     | 3.0 | 23.5 | 157.2 |  |  |  |



#### Dipesh Mehta

dipeshkumar.mehta@emkayglobal.com +91 22 6612 1253

#### Ayush Bansal

ayush.bansal@emkayglobal.com +91 22 6612 1344

#### Pulkit Chawla

pulkit.chawla@emkayglobal.com +91 22 6642 4258

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/08/2024 11:46 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions Refer to Important Disclosures at the end of this report on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

| Exhibit 1: Quarterly snapshot |         |         |         |         |         |  |  |  |
|-------------------------------|---------|---------|---------|---------|---------|--|--|--|
| Rs mn                         | Q4 FY24 | Q3 FY24 | QoQ (%) | Q4 FY23 | YoY (%) |  |  |  |
| Food delivery GOV             | 84,390  | 84,860  | (0.6)   | 65,690  | 28.5    |  |  |  |
| Blinkit GOV                   | 40,270  | 35,420  | 13.7    | 20,460  | 96.8    |  |  |  |
| Net sales                     | 35,620  | 32,880  | 8.3     | 20,560  | 73.2    |  |  |  |
| Operating expenses            | 34,760  | 32,370  | 7.4     | 22,814  | 52.4    |  |  |  |
| EBITDA                        | 860     | 510     | 69      | (2,254) | (138)   |  |  |  |
| Margins (%)                   | 2       | 2       | 90      | (11)    | 1,340   |  |  |  |
| Depreciation                  | 1400    | 1280    |         | 1338    |         |  |  |  |
| EBIT                          | (540)   | (770)   | (30)    | (3,592) | (85)    |  |  |  |
| Margins (%)                   | (2)     | (2)     | 80      | (17)    | 1,600   |  |  |  |
| Interest Paid                 | 200     | 180     |         | 158     |         |  |  |  |
| Other income                  | 2350    | 2190    |         | 1705    |         |  |  |  |
| Non-recurring items           | 0       | 0       |         | 1       |         |  |  |  |
| Pre-tax profit                | 1,610   | 1,240   | 30      | (2,044) | (179)   |  |  |  |
| Tax provided                  | -140    | -140    |         | -168    |         |  |  |  |
| Profit after tax              | 1,750   | 1,380   |         | (1,876) |         |  |  |  |
| Minority                      | -       | -       |         | 6       |         |  |  |  |
| Emkay Net profit              | 1,750   | 1,380   | 27      | (1,882) | (193)   |  |  |  |
| EPS (Rs)                      | 0.2     | 0.2     | 25.0    | (0.2)   | (187.0) |  |  |  |
|                               |         |         |         |         |         |  |  |  |

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates

| (Rs mn) Actual Estimate |        | % var           | iation | Comment  |           |  |
|-------------------------|--------|-----------------|--------|----------|-----------|--|
|                         | Actual | Emkay Consensus |        | Emkay    | Consensus |  |
| Net sales               | 35,620 | 34,767          | 34,855 | 2.5%     | 2.2%      | Revenue growth came ahead of estimates due to Blinkit outperformance.  |
| EBIT                    | (540)  | 40              | (191)  | NM       | NM        | Margins were below our estimates due to higher ESOP costs  |
| EBIT margin             | -1.5%  | 0.1%            | -0.5%  | -160 bps | -100 bps  |  |
| РАТ                     | 1,750  | 1,876           | 1,945  | -6.7%    | -10.0%    | PAT missed estimates due to operating performance miss, partly negated by higher other income and tax reversals. |

Source: Company, Bloomberg, Emkay Research

# Exhibit 3: Changes in estimates

| Rs mn           |          | FY25E    |        | FY26E    |          |        |  |
|-----------------|----------|----------|--------|----------|----------|--------|--|
| N9 IIII         | Old      | New      | Change | Old      | New      | Change |  |
| Net sales       | 1,70,963 | 1,72,573 | 0.9%   | 2,26,513 | 2,33,795 | 3.2%   |  |
| - YoY growth    | 42.1%    | 42.5%    |        | 32.5%    | 35.5%    |        |  |
| EBIT            | 10,888   | 6,078    | -44.2% | 25,048   | 23,199   | -7.4%  |  |
| EBIT margin (%) | 6.4      | 3.5      |        | 11.1     | 9.9      |        |  |
| Net profit      | 19,209   | 15,414   | -19.8% | 31,625   | 31,378   | -0.8%  |  |
| EPS (Rs)        | 2.1      | 1.7      | -19.8% | 3.5      | 3.4      | -0.8%  |  |

Source: Company, Emkay Research

# Exhibit 4: SoTP-based valuation

| Particular  | Methodology | Rs bn | Rs per share |
|---|-------------|-------|--------------|
| Valuation of food delivery business<br>(incl Hyperpure and Going out) | DCF         | 1,106 | 121          |
| Valuation of Quick commerce   | DCF         | 849   | 93           |
| Valuation of cash and other investments                               | Book value  | 154   | 17           |
| Total equity value (Rs bn)  |             | 2,109 | 231          |
| Target price  |             |       | 230          |

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 07/08/2024 11:46 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **Zomato: Consolidated Financials and Valuations**

| Profit & Loss               |          |          |          |          |          |
|-----------------------------|----------|----------|----------|----------|----------|
| Y/E Mar (Rs mn)             | FY22     | FY23     | FY24     | FY25E    | FY26E    |
| Revenue                     | 41,924   | 70,792   | 1,21,140 | 1,72,573 | 2,33,795 |
| Revenue growth (%)          | 110.3    | 68.9     | 71.1     | 42.5     | 35.5     |
| EBITDA                      | (18,508) | (12,105) | 420      | 11,924   | 29,299   |
| EBITDA growth (%)           | 0.0      | 0.0      | 0.0      | 2,738.9  | 145.7    |
| Depreciation & Amortization | 1,503    | 4,369    | 5,260    | 5,845    | 6,101    |
| EBIT                        | (20,011) | (16,474) | (4,840)  | 6,078    | 23,199   |
| EBIT growth (%)             | 0.0      | 0.0      | 0.0      | 0.0      | 281.7    |
| Other operating income      | 0        | 0        | 0        | 0        | 0        |
| Other income                | 4,949    | 6,815    | 8,470    | 9,774    | 10,905   |
| Financial expense           | 120      | 487      | 720      | 919      | 1,074    |
| РВТ                         | (15,182) | (10,146) | 2,910    | 14,933   | 33,030   |
| Extraordinary items         | 2,974    | 1        | 0        | 0        | 0        |
| Taxes                       | 20       | (436)    | (600)    | (481)    | 1,651    |
| Minority interest           | 138      | (3)      | 0        | 0        | 0        |
| Income from JV/Associates   | 3        | (3)      | 0        | 0        | 0        |
| Reported PAT                | (12,087) | (9,715)  | 3,510    | 15,414   | 31,378   |
| PAT growth (%)              | 0.0      | 0.0      | 0.0      | 339.1    | 103.6    |
| Adjusted PAT                | (15,061) | (9,716)  | 3,510    | 15,414   | 31,378   |
| Diluted EPS (Rs)            | (1.7)    | (1.1)    | 0.4      | 1.7      | 3.4      |
| Diluted EPS growth (%)      | 0.0      | 0.0      | 0.0      | 339.1    | 116.0    |
| DPS (Rs)                    | 0.0      | 0.0      | 0.0      | 0.0      | 0.0      |
| Dividend payout (%)         | 0.0      | 0.0      | 0.0      | 0.0      | 0.0      |
| EBITDA margin (%)           | (44.1)   | (17.1)   | 0.3      | 6.9      | 12.5     |
| EBIT margin (%)             | (47.7)   | (23.3)   | (4.0)    | 3.5      | 9.9      |
| Effective tax rate (%)      | (0.1)    | 4.3      | (20.6)   | (3.2)    | 5.0      |
| NOPLAT (pre-IndAS)          | (20,037) | (15,766) | (5,838)  | 6,274    | 22,039   |
| Shares outstanding (mn)     | 7,871.9  | 8,553.5  | 8,604.4  | 8,604.4  | 8,604.4  |

| Balance Sheet                |            |            |            |            |            |
|------------------------------|------------|------------|------------|------------|------------|
| Y/E Mar (Rs mn)              | FY22       | FY23       | FY24       | FY25E      | FY26E      |
| Share capital                | 7,643      | 8,364      | 8,680      | 8,680      | 8,680      |
| Reserves & Surplus           | 1,57,412   | 1,86,234   | 1,95,450   | 2,10,864   | 2,42,242   |
| Net worth                    | 1,65,055   | 1,94,598   | 2,04,130   | 2,19,544   | 2,50,922   |
| Minority interests           | (66)       | (66)       | (70)       | (70)       | (70)       |
| Deferred tax liability (net) | 0          | 0          | 0          | 0          | C          |
| Total debt                   | 0          | 404        | 0          | 0          | 0          |
| Total liabilities & equity   | 1,64,989   | 1,94,936   | 2,04,060   | 2,19,474   | 2,50,852   |
| Net tangible fixed assets    | 509        | 2,085      | 2,870      | 3,198      | 3,594      |
| Net intangible assets        | 799        | 9,905      | 7,540      | 5,491      | 3,440      |
| Net ROU assets               | 642        | 4,272      | 6,900      | 7,380      | 7,706      |
| Capital WIP                  | 6          | 75         | 179        | 1          | 1          |
| Goodwill                     | 12,093     | 47,166     | 47,170     | 47,170     | 50,601     |
| Investments [JV/Associates]  | 30,860     | 22,796     | 21,624     | 21,624     | 21,624     |
| Cash & equivalents           | 1,17,504   | 1,12,041   | 1,21,982   | 1,38,710   | 1,75,280   |
| Current assets (ex-cash)     | 10,857     | 17,647     | 25,294     | 32,795     | 39,911     |
| Current Liab. & Prov.        | 8,281      | 21,051     | 29,500     | 36,893     | 47,872     |
| NWC (ex-cash)                | 2,576      | (3,404)    | (4,206)    | (4,098)    | (7,962)    |
| Total assets                 | 1,64,989   | 1,94,936   | 2,04,060   | 2,19,474   | 2,50,852   |
| Net debt                     | (1,17,504) | (1,11,637) | (1,21,982) | (1,38,710) | (1,75,280) |
| Capital employed             | 1,64,989   | 1,94,936   | 2,04,060   | 2,19,474   | 2,50,852   |
| Invested capital             | 16,619     | 60,024     | 60,274     | 59,139     | 53,947     |
| BVPS (Rs)                    | 18.1       | 21.3       | 22.4       | 24.0       | 27.5       |
| Net Debt/Equity (x)          | (0.7)      | (0.6)      | (0.6)      | (0.6)      | (0.7)      |
| Net Debt/EBITDA (x)          | 6.3        | 9.2        | (290.4)    | (11.6)     | (6.0)      |
| Interest coverage (x)        | 0.0        | (0.1)      | 0.2        | 0.1        | 0.0        |
| RoCE (%)                     | (12.2)     | (5.4)      | 1.8        | 7.5        | 14.5       |

Source: Company, Emkay Research

| Cash flows                   |          |          |         |         |         |
|------------------------------|----------|----------|---------|---------|---------|
| Y/E Mar (Rs mn)              | FY22     | FY23     | FY24    | FY25E   | FY26E   |
| PBT                          | (15,182) | (10,146) | 2,910   | 14,933  | 33,030  |
| Others (non-cash items)      | 5,961    | 3,771    | 3,420   | 2,721   | 896     |
| Taxes paid                   | (192)    | (308)    | (1,050) | 481     | (1,651) |
| Change in NWC                | 2,483    | (1,759)  | 1,180   | (3,308) | 663     |
| Operating cash flow          | (6,930)  | (8,442)  | 6,460   | 14,827  | 32,938  |
| Capital expenditure          | (572)    | (1,014)  | (2,020) | (1,224) | (1,572) |
| Acquisition of business      | (209)    | (607)    | 0       | 0       | 0       |
| Interest & dividend income   | 1,126    | 4,904    | 6,180   | 9,124   | 10,205  |
| Investing cash flow          | (79,378) | 4,573    | (3,470) | 3,900   | (2,367) |
| Equity raised/(repaid)       | 90,000   | 40       | 230     | 0       | 0       |
| Debt raised/(repaid)         | (13)     | (231)    | (400)   | 0       | 0       |
| Payment of lease liabilities | (298)    | (1,055)  | (1,960) | 0       | 0       |
| Interest paid                | (7)      | (93)     | (20)    | 0       | 0       |
| Dividend paid (incl tax)     | 0        | 0        | 0       | 0       | 0       |
| Others                       | (2,184)  | 65       | 80      | (6,000) | (5,000) |
| Financing cash flow          | 87,498   | (1,274)  | (2,070) | (6,000) | (5,000) |
| Net chg in Cash              | 1,190    | (5,143)  | 920     | 12,728  | 25,570  |
| OCF                          | (6,930)  | (8,442)  | 6,460   | 14,827  | 32,938  |
| Adj. OCF (w/o NWC chg.)      | (4,447)  | (10,201) | 7,640   | 11,519  | 33,601  |
| FCFF                         | (7,502)  | (9,456)  | 4,440   | 13,603  | 31,366  |
| FCFE                         | (6,496)  | (5,039)  | 9,900   | 21,808  | 40,497  |
| OCF/EBITDA (%)               | 37.4     | 69.7     | 1,538.1 | 124.4   | 112.4   |
| FCFE/PAT (%)                 | 53.7     | 51.9     | 282.1   | 141.5   | 129.1   |
| FCFF/NOPLAT (%)              | 37.4     | 60.0     | (76.1)  | 216.8   | 142.3   |

Source: Company, Emkay Research

Source: Company, Emkay Research

| Valuations and key Ratios |         |         |         |       |        |  |  |  |
|---------------------------|---------|---------|---------|-------|--------|--|--|--|
| Y/E Mar                   | FY22    | FY23    | FY24    | FY25E | FY26E  |  |  |  |
| P/E (x)                   | (117.4) | (182.6) | 505.5   | 115.1 | 56.5   |  |  |  |
| P/CE(x)                   | 0.0     | 0.0     | 202.3   | 83.5  | 47.3   |  |  |  |
| P/B (x)                   | 10.7    | 9.1     | 8.7     | 8.1   | 7.1    |  |  |  |
| EV/Sales (x)              | 39.4    | 23.5    | 13.6    | 9.5   | 6.8    |  |  |  |
| EV/EBITDA (x)             | (89.2)  | (137.3) | 3,933.9 | 137.2 | 54.6   |  |  |  |
| EV/EBIT(x)                | 0.0     | 0.0     | 0.0     | 252.2 | 64.5   |  |  |  |
| EV/IC (x)                 | 85.0    | 25.8    | 25.7    | 25.9  | 27.7   |  |  |  |
| FCFF yield (%)            | (0.5)   | (0.6)   | 0.3     | 0.9   | 2.1    |  |  |  |
| FCFE yield (%)            | (0.4)   | (0.3)   | 0.6     | 1.3   | 2.4    |  |  |  |
| Dividend yield (%)        | 0.0     | 0.0     | 0.0     | 0.0   | 0.0    |  |  |  |
| DuPont-RoE split          |         |         |         |       |        |  |  |  |
| Net profit margin (%)     | (35.9)  | (13.7)  | 2.9     | 8.9   | 13.4   |  |  |  |
| Total asset turnover (x)  | 0.3     | 0.4     | 0.6     | 0.8   | 1.0    |  |  |  |
| Assets/Equity (x)         | 1.0     | 1.0     | 1.0     | 1.0   | 1.0    |  |  |  |
| RoE (%)                   | (12.2)  | (5.4)   | 1.8     | 7.3   | 13.3   |  |  |  |
| DuPont-RoIC               |         |         |         |       |        |  |  |  |
| NOPLAT margin (%)         | (47.8)  | (22.3)  | (4.8)   | 3.6   | 9.4    |  |  |  |
| IC turnover (x)           | 2.8     | 1.8     | 2.0     | 2.9   | 4.1    |  |  |  |
| RoIC (%)                  | (131.5) | (41.1)  | (9.7)   | 10.5  | 39.0   |  |  |  |
| Operating metrics         |         |         |         |       |        |  |  |  |
| Core NWC days             | 22.4    | (17.6)  | (12.7)  | (8.7) | (12.4) |  |  |  |
| Total NWC days            | 22.4    | (17.6)  | (12.7)  | (8.7) | (12.4) |  |  |  |
| Fixed asset turnover      | 2.1     | 1.5     | 1.6     | 2.2   | 2.9    |  |  |  |
| Opex-to-revenue (%)       | 131.6   | 97.4    | 75.9    | 67.5  | 59.7   |  |  |  |

Source: Company, Emkay Research

This report is intended for team emkay @ whitemarguesolutions.com use and downloaded at 07/08/2024 11:46 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

| Date      | Closing<br>Price (INR) | TP (INR) | Rating | Analyst           |
|-----------|------------------------|----------|--------|-------------------|
| 09-May-24 | 195                    | 230      | Buy    | Dipeshkumar Mehta |
| 31-Mar-24 | 182                    | 170      | Buy    | Dipeshkumar Mehta |
| 01-Mar-24 | 167                    | 170      | Buy    | Dipeshkumar Mehta |
| 08-Feb-24 | 144                    | 170      | Buy    | Dipeshkumar Mehta |
| 31-Dec-23 | 124                    | 140      | Buy    | Dipeshkumar Mehta |
| 30-Nov-23 | 119                    | 140      | Buy    | Dipeshkumar Mehta |
| 29-Nov-23 | 117                    | 140      | Buy    | Dipeshkumar Mehta |
| 05-Nov-23 | 117                    | 140      | Buy    | Dipeshkumar Mehta |
| 02-Oct-23 | 102                    | 120      | Buy    | Dipeshkumar Mehta |
| 04-Aug-23 | 95                     | 110      | Buy    | Dipeshkumar Mehta |
| 02-Jul-23 | 75                     | 90       | Buy    | Dipeshkumar Mehta |
| 20-May-23 | 65                     | 90       | Buy    | Dipeshkumar Mehta |
| 01-Apr-23 | 51                     | 90       | Buy    | Dipeshkumar Mehta |
| 10-Feb-23 | 53                     | 90       | Buy    | Dipeshkumar Mehta |
| 02-Jan-23 | 60                     | 90       | Buy    | Dipeshkumar Mehta |
| 11-Nov-22 | 73                     | 90       | Buy    | Dipeshkumar Mehta |
| 04-Oct-22 | 64                     | 90       | Buy    | Dipeshkumar Mehta |
| 28-Sep-22 | 58                     | 90       | Buy    | Dipeshkumar Mehta |

Source: Company, Emkay Research

# **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 07/08/2024 11:46 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. It is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 07/08/2024 11:46 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup>An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of May 14, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of May 14, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the May 14, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

## **Emkay Rating Distribution**

| Ratings | Expected Return within the next 12-18 months. |  |
|---------|---|--|
| BUY     | >15% upside                                   |  |
| ADD     | 5-15% upside                                  |  |
| REDUCE  | 5% upside to 15% downside                     |  |
| SELL    | <15% downside                                 |  |

## Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 07/08/2024 11:46 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### OTHER DISCLAIMERS AND DISCLOSURES:

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation from the subject Company in the past 12 months. EGFSL or its associates may have received compensation from the subject Company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.